Peramivir[2]

Updated: 2026-09-16

Overview

Peramivir is an antiviral medication belonging to the neuraminidase inhibitor class, specifically developed for the treatment of influenza. It is administered intravenously, making it particularly useful for patients who cannot tolerate oral medications or require rapid therapeutic effects. Peramivir was approved for medical use in several countries, including the United States, Japan, and South Korea. The drug works by inhibiting the neuraminidase enzyme, which is essential for the replication and spread of influenza viruses. This mechanism makes it effective against both influenza A and B strains. Peramivir is typically used in hospital settings for patients with severe or complicated influenza infections.

Physical and Chemical Properties

Peramivir is a white to off-white crystalline powder with a molecular weight of 328.41 g/mol. Its molecular formula is C15H28N4O4, and it is highly soluble in water, which facilitates its intravenous administration. The compound is stable under recommended storage conditions but should be protected from light and moisture to maintain efficacy. The exact melting and boiling points of Peramivir are not widely documented, but it is known to degrade under extreme temperatures. Its solubility profile and stability make it suitable for formulation in sterile injectable solutions.

Main Applications

Peramivir is primarily used for the treatment of acute uncomplicated influenza in adults and pediatric patients. It is particularly valuable in cases where oral or inhaled antiviral medications are not feasible, such as in hospitalized patients or those with severe nausea. The drug is administered as a single intravenous dose, which simplifies treatment regimens compared to other antivirals that require multiple doses. In addition to its use in treating active infections, Peramivir has been studied for prophylactic applications during influenza outbreaks. However, its primary indication remains the treatment of confirmed influenza cases, especially those caused by strains resistant to other neuraminidase inhibitors.

Safety and Storage

Peramivir should be stored at controlled room temperature (20-25°C) in its original packaging to protect it from light and moisture. Improper storage can lead to degradation, reducing the drug's effectiveness. Healthcare providers should inspect the solution for particulate matter or discoloration before administration. Safety concerns include the potential for allergic reactions, neuropsychiatric events (such as hallucinations or delirium), and other side effects like diarrhea and nausea. Patients with a history of hypersensitivity to neuraminidase inhibitors should avoid Peramivir. Medical supervision is essential during treatment to monitor for adverse effects.

B2B Procurement Guide

When procuring Peramivir in bulk, buyers should ensure that suppliers are compliant with Good Manufacturing Practice (GMP) standards and hold the necessary pharmaceutical licenses. Due to its status as a prescription drug, transactions may require additional documentation and verification processes. The reference price for Peramivir ranges approximately between $50 and $100 per vial, though prices can vary based on order volume and regional regulations. Buyers should also consider logistics, such as cold chain requirements for certain formulations, to maintain product integrity during transportation.